VieCure provides Halo Intelligence™, an artificial-intelligence–driven platform that combines structured patient data, a clinical inference engine, and workflow automation to assist oncologists in selecting evidence-based, personalized cancer treatments. Designed as both a smart EMR and real-time decision-support tool, Halo helps reduce clinical complexity, increase guideline-compliant care, and boost practice efficiency. The system is currently used to manage care for nearly 30,000 patients across a growing national network of community oncology locations. Reported outcomes include an approximately eight-fold increase in tumor sequencing rates, a two-fold rise in guideline-aligned treatment plans, and measurable gains in oncologist capacity and workflow productivity. VieCure partners with cancer centers and life-science organizations throughout the United States. Proceeds from its latest financing will be used to expand product capabilities and accelerate market penetration among community oncology practices. Board additions and operational support from investor Mitch Rales’ New Bearing firm aim to instill world-class operating discipline as the company scales.

Total raised

$113M

Funding rounds

3

Latest round

Equity

Latest activity

Jan 2026